EUVIMEDEUVIMED entdecken
Open Access

Benefits of Combining Circulating Tumor DNA With Tissue and Longitudinal Circulating Tumor DNA Genotyping in Advanced Solid Tumors: SCRUM-Japan MONSTAR-SCREEN-1 Study

Takao Fujisawa iD, Yoshiaki Nakamura iD, Hideaki Bando iD, Chigusa Morizane iD, Masafumi Ikeda iD, Norio Nonomura, Nobuaki Matsubara iD, Hiroji Iwata iD, Yoichi Naito iD, Susumu Okano, Daisuke Aoki iD, Kenichi Harano iD und 30 weitere

JCO Precision Oncology · 2025

DOI: 10.1200/po.24.00283 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Precision Oncology, 2025. Verfasst von Takao Fujisawa und 41 weiteren Autor:innen. Beteiligte Einrichtung: Translational Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE The utility of capturing heterogeneity by circulating tumor DNA (ctDNA) genotyping combined with tissue analysis or applying it in a sequential manner remains uncertain. METHODS We assessed the clinical value of ctDNA genotyping using data from 2,187 patients with advanced solid tumors enrolled in SCRUM-Japan MONSTAR-SCREEN-1, a nationwide cancer genome screening project, which examined ctDNA from longitudinally collected blood samples and tumor tissue samples (UMIN 000036749). RESULTS Among 667 patients with both baseline ctDNA and tissue genotyping results, 51 (7.6%) had actionable biomarkers identified exclusively through ctDNA genotyping. The most frequent targets of genotype-matched therapy guided by solely ctDNA were immune checkpoint, estrogen receptor, and poly(ADP-ribose) polymerase (PARP). Comparison of objective response rates (ORRs) and progression-free survival (PFS) between patients treated based on tissue versus ctDNA alone showed no significant difference, with ORRs of 34.0% versus 23.1% ( P = .54) and a median PFS of 11.5 versus 13.8 months (hazard ratio [HR], 1.4 [95% CI, 0.72 to 2.80]), respectively. Among 924 patients undergoing sequential ctDNA genotyping, the detection of actionable biomarkers increased from 63.2% to 72.5% following subsequent ctDNA. Targets for genotype-matched therapy guided by subsequent ctDNA alone commonly included PARP, immune checkpoint, and BRAF. The ORR was 23.2% and 26.7% ( P = .75), and the median PFS was 5.2 and. 3.7 months (HR, 1.5 [95% CI, 0.79 to 2.80]) for genotype-matched therapy based on initial versus subsequent ctDNA alone, respectively. CONCLUSION Combining ctDNA with tissue analysis, followed by sequential ctDNA assessments, effectively enhances the identification of actionable biomarkers. This strategy facilitates clinically beneficial, genetically informed therapies, underscoring its significant value in precision oncology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Circulating Tumor DNANeoplasmsHumansFemaleMaleMiddle AgedAgedJapanBiomarkers, TumorGenotypeAdultAged, 80 and over

Substanzen

Circulating Tumor DNABiomarkers, Tumor

Autor:innen und Institutionen

  • Translational Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan.
  • Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
  • Course of Advanced Clinical Research of Cancer, Juntendo University Graduate School of Medicine, Tokyo, Japan.
  • Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
  • International Research Promotion Office, National Cancer Center Hospital East, Kashiwa, Japan.
  • Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan.

ORCID-Profile: Takao Fujisawa, Yoshiaki Nakamura, Hideaki Bando, Chigusa Morizane, Masafumi Ikeda, Nobuaki Matsubara, Hiroji Iwata, Yoichi Naito, Daisuke Aoki, Kenichi Harano, Naoya Yamazaki, Kenjiro Namikawa, Makoto Ueno, Shigenori Kadowaki, Eiji Oki, Ken Kato, Yoshito Komatsu, Taroh Satoh, Tadamichi Denda, Tetsuya Hamaguchi, Kentaro Yamazaki, Hisateru Yasui, Masahiro Goto, Yu Sunakawa, Tomoyuki Otsuka, Hikaru Abutani, Hanna Tukachinsky, Jessica K Lee, Geoffrey R Oxnard, Naomi Kuramoto, Satoshi Horasawa, Hiroya Taniguchi, Takayuki Yoshino

Zitieren

APA

Fujisawa, T., Nakamura, Y., Bando, H., Morizane, C., Ikeda, M., Nonomura, N., Matsubara, N., Iwata, H., Naito, Y., Okano, S., Aoki, D., Harano, K., Yamazaki, N., Namikawa, K., Ueno, M., Kadowaki, S., Oki, E., Kato, K., Komatsu, Y., …, & Yoshino, T. (2025). Benefits of Combining Circulating Tumor DNA With Tissue and Longitudinal Circulating Tumor DNA Genotyping in Advanced Solid Tumors: SCRUM-Japan MONSTAR-SCREEN-1 Study. JCO Precision Oncology. https://doi.org/10.1200/po.24.00283

Vancouver

Fujisawa T, Nakamura Y, Bando H, Morizane C, Ikeda M, Nonomura N, et al. Benefits of Combining Circulating Tumor DNA With Tissue and Longitudinal Circulating Tumor DNA Genotyping in Advanced Solid Tumors: SCRUM-Japan MONSTAR-SCREEN-1 Study. JCO Precision Oncology. 2025. doi:10.1200/po.24.00283

BibTeX
@article{Fujisawa2025,
  author = {Fujisawa, Takao and Nakamura, Yoshiaki and Bando, Hideaki and Morizane, Chigusa and Ikeda, Masafumi and Nonomura, Norio and Matsubara, Nobuaki and Iwata, Hiroji and Naito, Yoichi and Okano, Susumu and Aoki, Daisuke and Harano, Kenichi and Yamazaki, Naoya and Namikawa, Kenjiro and Ueno, Makoto and Kadowaki, Shigenori and Oki, Eiji and Kato, Ken and Komatsu, Yoshito and Satoh, Taroh and Esaki, Taito and Denda, Tadamichi and Hamaguchi, Tetsuya and Yamazaki, Kentaro and Matsuhashi, Nobuhisa and Yasui, Hisateru and Satake, Hironaga and Nishina, Tomohiro and Takahashi, Naoki and Goto, Masahiro and Sunakawa, Yu and Kato, Takeshi and Otsuka, Tomoyuki and Abutani, Hikaru and Tukachinsky, Hanna and Lee, Jessica K and Oxnard, Geoffrey R and Kuramoto, Naomi and Horasawa, Satoshi and Sakamoto, Yasutoshi and Taniguchi, Hiroya and Yoshino, Takayuki},
  title = {Benefits of Combining Circulating Tumor DNA With Tissue and Longitudinal Circulating Tumor DNA Genotyping in Advanced Solid Tumors: SCRUM-Japan MONSTAR-SCREEN-1 Study},
  journal = {JCO Precision Oncology},
  year = {2025},
  doi = {10.1200/po.24.00283}
}
Kostenlos starten →